KTTA
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Pasithea Therapeutics Corp. (KTTA) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (C). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B+ (3.6) | C+ (2.6) | C+ (2.5) | C (2.3) | C+ (2.6) | C+ (2.7) |
| 2026-11-06 | B+ (3.8) | C+ (2.6) | C+ (2.6) | C (2.2) | C+ (2.7) | C+ (2.7) |
| 2026-10-30 | B+ (3.6) | C (2.5) | C+ (2.6) | C- (2.0) | C+ (2.7) | C+ (2.7) |
| 2026-10-23 | B+ (3.6) | C (2.5) | C+ (2.6) | C (2.2) | C+ (2.6) | C+ (2.7) |
| 2026-10-16 | B+ (3.6) | C (2.5) | C+ (2.6) | C- (2.1) | C+ (2.6) | C+ (2.7) |